
Sign up to save your podcasts
Or


Bioprocess Online Chief Editor Matt Pillar gives some background on his provocative new article, “Is Biopharma's Response To Coronavirus Off The Mark?” He also discusses his feature story, “The Perilous Development of a Potential Biologic Blockbuster,” and why it’s one of the most read articles on his site. (For additional information on Life Science Connect and its network of online resources, visit Life Science Connect).
By Life Science ConnectBioprocess Online Chief Editor Matt Pillar gives some background on his provocative new article, “Is Biopharma's Response To Coronavirus Off The Mark?” He also discusses his feature story, “The Perilous Development of a Potential Biologic Blockbuster,” and why it’s one of the most read articles on his site. (For additional information on Life Science Connect and its network of online resources, visit Life Science Connect).